



At Risk 228 87 24 3 Events 0 103 148 165



	Male			
At Risk	138	44	13	2
Events	0	76	103	112
	Female			

At Risk

Events



Events

Male, Asymptomatic

Female, Asymptomatic

Female, Symptomatic and ambulatory

Female, In bed <50% of the day

Male, Symptomatic and ambulatory

Male, In bed <50% of the day


Male, In bed > 50% of the day

	0.00				
		Ö	10	20	30
			Survival	time, months	
	Male, Asymptomatic — N	Male, In	bed <50% of the day	— Female, A	symptomatic
•	Male, Symptomatic and ambulatory — M	Male, In	bed > 50% of the day	— Female, S	ymptomatic and ambu
		At Ris	k		
	Male, Asymptomatic	36	18	6	1
	Male, Symptomatic and ambulatory	71	20	5	1
	5.4 L L L =00/ C/L L		_	_	_


0.00				
	Ö	10	20	30
		Survival	time, months	
Male, Asymptomatic —	Male, In bed	<50% of the day	— Female, As	symptomatic
Male, Symptomatic and ambulatory —	Male, In bed	> 50% of the day	— Female, Sy	mptomatic and amb
	At Risk			
Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Famala Symptomatic and ambulatory	. 40	၁၁	0	1

U	Survival	time, months	30
Male, In b	ed <50% of the day	— Female, A	symptomatic
Male, In b	ed > 50% of the day	— Female, S	ymptomatic and amb
At Risk			
36	18	6	1
71	20	5	1
29	6	2	0
1	0	0	0
27	13	2	0
42	23	8	1
21	7	1	0
	Male, In b At Risk 36 71 29 1 27 42	Survival Male, In bed <50% of the day Male, In bed > 50% of the day At Risk 36	Survival time, months Male, In bed <50% of the day — Female, As Male, In bed > 50% of the day — Female, S At Risk 36

	U	Survival	time, months	30
Male, Asymptomatic — N	/lale, In bed	<50% of the day	— Female, As	symptomatic
Male, Symptomatic and ambulatory — M	Male, In bed	> 50% of the day	— Female, Sy	mptomatic and amb
	At Risk			
Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female In hed <50% of the day	21	7	1	0



At Risk 228 87 24 3
CUM EVENTS 0 103 148 165




iviale i enia

Ma	ale			
At Risk 1	38	44	13	2
CUM EVENTS	0	76	103	112
Fei	male			

isk 90

At Risk	90	43	11	1
UM EVENTS	0	27	45	53



CUM EVENTS

Male, Asymptomatic

Female, Asymptomatic

Female, Symptomatic and ambulatory


Female, In bed <50% of the day

Male, Symptomatic and ambulatory


Male, In bed <50% of the day

Male, In bed > 50% of the day

Ö	10	20	30
	Survival	time, months	
Male, In	bed <50% of the day	Female, A	symptomatic
Male, In	bed > 50% of the day	— Female, S	Symptomatic and ambu
At Risk	ζ.		
36	18	6	1
	_	_	1
		2	0
1	0	0	0
27	13	2	0
42	23	8	1
21	7	1	0
	Male, In Male, In At Risk 36 71 29 1 27 42	Male, In bed <50% of the day Male, In bed > 50% of the day At Risk 36	Survival time, months Male, In bed <50% of the day — Female, A Male, In bed > 50% of the day — Female, S At Risk 36



CUM EVENTS	228	87	24	3
N RISK	0	103	148	165



iviale i ema

CUM EVENTS 138	44	13	2	
N RISK 0	76	103	112	
Fema	le			

CUM EVENTS	90	

N RISK


Male

0

43
27

,	11
,	45

1



	Survival time, months						
Male, Asymptomatic — I	Male, In be	ed <50% of the day	— Female, As	symptomatic			
Male, Symptomatic and ambulatory — I	lle, Symptomatic and ambulatory — Male, In bed		— Female, Sy	mptomatic and ambu			
	CUM EV	'ENTS					
Male, Asymptomatic	36	18	6	1			
Male, Symptomatic and ambulatory	71	20	5	1			
Male, In bed <50% of the day	29	6	2	0			
Male, In bed > 50% of the day	1	0	0	0			
Female, Asymptomatic	27	13	2	0			
Female, Symptomatic and ambulatory	42	23	8	1			
Female, In bed <50% of the day	21	7	1	0			
	N RISK						
Male, Asymptomatic	0	13	24	28			
Male, Symptomatic and ambulatory	0	39	51	54			

Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female, In bed <50% of the day	21	7	1	0


Male, In bed <50% of the day

Male, In bed > 50% of the day

Female, Asymptomatic

Female, Symptomatic and ambulatory

Female, In bed <50% of the day




	Male			
At Risk	138	44	13	2
Events	0	76	103	112
	Female			


At Risk

Events

ırvi		Survivar	ume, monuis		
omatic	-	Male, In bed <50% of the day	Female, Asymptomatic		— Fei
n I	Male, Asy	mptomatic			
At Risk	36	18	6	1	
Events	0	13	24	28	
1	Male, Syr	mptomatic and ambulatory			
At Risk	71	20	5	1	
Events	0	39	51	54	
1	Male, In t	ped <50% of the day			
At Risk	29	6	2	0	
Events	0	22	26	28	
1	Male, In t	ped > 50% of the day			
At Risk	1	0	0	0	
Events	0	1	1	1	
1	Female, <i>i</i>	Asymptomatic			
At Risk	27	13	2	0	
Events	0	4	8	9	
1	Female, S	Symptomatic and ambulatory			
At Risk	42	23	8	1	
Events	0	12	22	28	
	Female, I	n bed <50% of the day			
At Risk	21	7	1	0	
Events	0	11	15	16	





At Risk 228 87 24 3 Events 0 103 148 165



At Risk 227 87 24 3

Events 0 102 147 218






At Risk	98	97	94	83	61	0
Events	0	0	2	7	17	24

Drug B
At Risk 102

Events

)2 1



Drug A, I
Drug A, II
Drug A, III
Drug B, II
Drug B, III

At Risk


Drug A, I

Drug B, III


Drug B, I	33	33	33	28	23	0
Drug A, II	32	32	30	27	23	0
Drug B, II	36	36	32	23	17	0
Drug A, III	31	30	29	26	16	0
Drua B. III	33	33	30	24	15	0

Events

Drug A, I	0	0	0	4	7	9
Drug B, I	0	0	0	3	5	9
Drug A, II	0	0	1	2	3	5
Drug B, II	0	0	2	8	12	12
Drug A, III	0	0	1	1	7	1(



CUM EVENTS 0 0 6 24 43 57




Drug A Drug

At Risk	98	97	94	83	61	0
CUM EVENTS	0	0	2	7	17	24

Drug B

Drug A

At Risk	102	102	95	75	55	0
CUM EVENTS	0	0	4	17	26	33



Drug A, I
Drug A, II
Drug A, III
Drug B, II
Drug B, III

30

22

0

At Risk

35


Drug A, I 35

Drug B, I	33	33	33	28	23	0
Drug A, II	32	32	30	27	23	0
Drug B, II	36	36	32	23	17	0
Drug A, III	31	30	29	26	16	0
Drug B, III	33	33	30	24	15	0

35

CUM EVENTS

•	OIVI L V LIV	110				
Drug A, I	0	0	0	4	7	9
Drug B, I	0	0	0	3	5	9
Drug A, II	0	0	1	2	3	5
Drug B, II	0	0	2	8	12	12
Drug A, III	0	0	1	1	7	10
Drug B, III	0	0	2	6	9	12




At Risk	98	97	94	83	61	0
Events	0	0	2	7	17	24

Drug B
At Risk 102

Events


)2 1

Cumulative (***)	Ō	5	10 Months to De	15 ath/Censor	20	25			
$\ddot{\circ}$		۸, III							
		— Drug B, I — Drug B, II — Drug B, III							
	Drug A, I								
At Risk	35	35	35	30	22	0			
Events	0	0	0	4	7	9			
	Drug B, I								
At Risk	33	33	33	28	23	0			
Events	0	0	0	3	5	9			
	Drug A, II								
At Risk	32	32	30	27	23	0			
Events	0	0	1	2	3	5			
	Drug B, II								
At Risk	36	36	32	23	17	0			
Events	0	0	2	8	12	12			
	Drug A, III								
At Risk		30	29	26	16	0			
Events	0	0	1	1	7	10			
	Drug B, III								
At Risk		33	30	24	15	0			
Events	0	0	2	6	9	12			




At Risk 200 199 189 158 116 0


Events 0 0 6 24 43 57




At Risk 200 199 189 158 116 0

Events 0 0 6 24 43 57







At Risk 228 87 24 3 Events 0 103 148 165